Pharmacokinetics and Pharmacodynamics of Pegfilgrastim in Subjects With Various Degrees of Renal Function
| Autor: | Suzanne Swan, Bing-Bing Yang, Anna Kido, John T. Sullivan, Margaret Salfi |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Filgrastim Neutrophils Injections Subcutaneous Urology Renal function Pharmacology Severity of Illness Index Polyethylene Glycols Leukocyte Count Subcutaneous injection Pharmacokinetics Renal Dialysis Granulocyte Colony-Stimulating Factor medicine Humans Pharmacology (medical) Aged Kidney business.industry Middle Aged Recombinant Proteins medicine.anatomical_structure Pharmacodynamics Absolute neutrophil count Female Kidney Diseases business Pegfilgrastim medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 48:1025-1031 |
| ISSN: | 0091-2700 |
| DOI: | 10.1177/0091270008320318 |
| Popis: | A phase I study was conducted to evaluate the effects of renal function on the pharmacokinetics and pharmacodynamics (absolute neutrophil count [ANC]) of pegfilgrastim in nonneutropenic subjects. Thirty subjects categorized into 5 renal function groups (normal, mildly impaired, moderately impaired, severely impaired, and end-stage renal disease) received 1 subcutaneous injection of pegfilgrastim at 6 mg. The ANC profiles after pegfilgrastim administration were similar across different renal function groups. No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for C(max) and from 7469 to 8513 ng x h/mL for AUC. Results suggest that the kidney has no important role in the elimination of pegfilgrastim. Therefore, no dosage adjustment for renal impairment is indicated for pegfilgrastim. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text